KMCRIC

The efficacy of Shenghua Decoction supplementation after early medical abortion: A meta-analysis of randomized controlled trials.

Li HF, Chen WM, Shen HL, Feng ZF, Yang Y, Shen QH.

Complement Ther Med.

2022

69

102848.

10.1016/j.ctim.2022.102848.

35779783

http://www.ncbi.nlm.nih.gov/pubmed/35779783

*Abortion, Induced
*Dietary Supplements/adverse effects
*Drugs, Chinese Herbal/adverse effects
Female
Humans
Pregnancy
Randomized Controlled Trials as Topic
Medical abortion
Meta-analysis
Randomized controlled trial
Shenghua Decoction
Traditional Chinese medicine

Medical abortion; Meta-analysis; Randomized controlled trial; Shenghua Decoction; Traditional Chinese Medicine

의료적 인공 임신 중절; 메타분석; 무작위배정 비교임상연구; 생화탕; 중의학

KMCRIC 비평 보기 +

Aims: Shenghua Decoction (SHD) is a well-known classic herbal formula documented in traditional Chinese medicine (TCM) that has been widely applied during the postpartum period in Chinese communities for several years. We conducted this systematic review and meta-analysis to explore the influence of SHD as an adjuvant treatment for early medical abortion using a combination of mifepristone followed by misoprostol.

Methods: This systematic review and meta-analysis was reported using 2020 PRISMA guidelines. Eight databases were searched from their establishment to February 28, 2022, for randomized controlled trials (RCTs): PubMed, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure, the Chinese BioMedical database, the Chinese Scientific Journal Database, and the Wanfang database. The Grading of Recommendations Assessment, Development, and Evaluation estimated the quality of evidence.

Results: Sixteen RCTs involving 3016 patients were included in the meta-analysis. Overall, compared with no treatment as the control group after early medical abortion, patients treated with SHD were associated with a higher complete abortion rate (RR: 1.14; 95% CI: 1.10 - 1.18; P < 0.01, I2 = 26%, moderate quality), lower incomplete abortion rate (RR: 0.31; 95% CI: 0.24 - 0.41; P < 0.01, I2 = 0%, moderate quality), and lower viable pregnancy rate (RR: 0.26; 95% CI: 0.11 - 0.62; P < 0.01, I2 = 0%, moderate quality). Additionally, SHD supplementation was associated with reduced the induction-abortion time, duration of vaginal bleeding and menstrual recovery time.

Conclusion: Our findings suggest that SHD supplementation may be beneficial for women seeking a medical abortion before the 7-week gestational period and no adverse events in the experimental group were reported. However, the methodological quality of the included RCTs was unsatisfactory, and therefore it is necessary to further verify the effectiveness of SHD using standardized studies of rigorous design.

Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.

N

영어